Mirus Bio launches new TransIT-PRO transfection kit for biotherapeutic protein production

Mirus Bio now offers a new transfection kit ideal for biotherapeutic protein production in large pharma and biotech settings. Mirus Bio's new TransIT-PRO™ Kit will decrease time to produce usable protein by maximizing target protein yields through transient transfection. TransIT-PRO™ Kit uses animal origin free components designed for high and reproducible protein yield in suspension CHO and 293 derived cells. Since it is compatible with varied media formulations, the same media can be used for both transient and stable expression. TransIT-PRO™ outperforms linear PEI in protein yield and reproducibility while providing a cost-effective alternative to FreeStyle™ MAX.

With TransIT-PRO™ you will:

  • Achieve high protein yield in suspension CHO and 293 cells
  • Experience compatibility with multiple CHO media formulations
  • Obtain reproducible protein expression with minimal optimization

Mirus Bio LLC


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Interactions between SARS-CoV-2 S protein and ACE2 receptor using fluorescence correlation spectroscopy